论文部分内容阅读
目的:观察非索非那定联合孟鲁司治疗儿童上气道咳嗽综合征的临床疗效及安全性。方法:112例儿童上气道咳嗽综合征(UACS)患者按随机数字表分为观察组和对照组各56例。观察组予非索非那定片30 mg,po,bid,孟鲁司特钠片5 mg,po,qn。对照组给予非索非那定片30 mg,po,bid。观察两组疗效及药品不良反应。结果:观察组总有效率96.4%,对照组总有效率80.4%,两组比较差异有统计学意义(P<0.05)。观察组患者在3 d、7 d咳嗽消失及平均咳嗽消失时间明显优于对照组(P<0.05),均未出现明显不良反应。结论:非索非那定联合孟鲁司治疗儿童上气道咳嗽综合征的临床疗效及咳嗽消失情况优于单用非索非那定。
Objective: To observe the clinical efficacy and safety of fexofenadine combined with montelukast in children with upper respiratory tract cough syndrome. Methods: One hundred and twelve children with upper airway cough syndrome (UACS) were divided into observation group and control group according to random number table. The observation group was given fexofenadine tablets 30 mg, po, bid, Montelukast sodium tablets 5 mg, po, qn. The control group was given fexofenadine tablets 30 mg, po, bid. The curative effect and adverse drug reaction of the two groups were observed. Results: The total effective rate was 96.4% in the observation group and 80.4% in the control group, with significant difference between the two groups (P <0.05). In the observation group, the disappearance of cough and the mean disappearance of cough on day 3 and day 7 were significantly better than those of the control group (P <0.05). No significant adverse reactions occurred in the observation group. Conclusion: The clinical efficacy and cough disappearance of fexofenadine combined with montelukast in children with upper airway cough syndrome are superior to those of fexofenadine alone.